Charles Mizrahi moved over to Angel Publishing a year or so ago, so we’re seeing a lot more ads for his Inevitable Wealth Portfolio. And the latest one pretty well bangs us over the head with the huge promises… including a “make 109 times your money” in the next decade headline, which is a dramatic […]
Articles
- Most Relevant
- Most Recent
Today we’ve got a two-fer — two different big publishers are teasing different “liquid biopsy” stocks, and I’m no expert on the technology or the prospects for this diagnostic “trend” that we’ve been hearing more about… so I’ll just sift the clues, identify the companies, and let you chatter about their merits amongst yourselves. The […]
David Gardner at the Motley Fool is usually the “growth” guy — he’s the one who has most famously grabbed on to “story” stocks when they were crazy expensive but had big growth potential, and held on for gains of several thousand percent (Netflix, Priceline, etc.). So it caught my eye that he’s recommending a […]
This is not the first time a teaser stock idea has been pitched to us as “perfect” or “almost perfect,” of course, but using such definitive terms always catches my attention. (Yet another weakness of your friendly neighborhood Gumshoe, I can’t resist the pursuit of perfection.) And as he’s done several times before, this time […]
There’s nothing like a nice, mysterious teaser pitch to greet you upon a return from vacation — I’ve been traveling for ten days or so, returned to the frozen north feeling perhaps slightly grumpy about sitting at my desk instead of at the beach… … but this morning I saw the spiel about Chuck de […]
Today we’ve broken the Friday File up into two parts for your convenience — part one is all about a couple high-dividend technology stocks that look appealing to me right now, including one I bought a bit more of recently, and this one’s about a teaser that’s being foist upon the world by Bill pantaloon […]
One of the introductions to this ad reads thus: “Use this code: CKUCU. “If you go to your brokerage account today… type in stock ticker COF… and enter the code’s 5 letters – you’ll receive $920 within 5 minutes.” But the more fun introduction, the one that’s probably really getting peoples’ attention, is this: “Use […]
Today we have the attention-getting “Say NO to Lithium Stocks” headline from Dr. Kent Moors in an ad for his Energy Advantage newsletter… and, as you will probably have already guessed, it’s really more of a “Say No to Lithium Stocks (except for this awesome little one I want to sell you one)” ad. So, […]
I haven’t looked at a spiel from Michael Robinson in quite some time, so when a few readers forwarded his latest pitch for the Nova-X Report I thought I’d take a quick look for you. That newsletter, which is currently being sold for $99, is getting the hype treatment with his pitch about marijuana investing, […]
The response was pretty overwhelmingly positive when I started sending out those “Trade Note” emails this week… so I’ll stick with it for a while, at least, and see how this goes. What does that mean? Same day buy/sell notes about my Real Money Portfolio will be sent to the Irregulars going forward, in hopes […]
Our old friend and teaser adversary Louis Navellier hasn’t been spinning so many teasers lately — I like to think he’s terrified of the Stock Gumshoe, and of the way that my brilliant, amusing, and awe-inspiring commentaries tear his teasers to shreds and lay waste to his marketing efforts. Sure, it’s a fantasy, but we […]
I’m always interested to see what kind of big-growth ideas are being teased, particularly in a market that already feels so expensive, so a Cabot pitch caught my eye again this week — this time it’s from Mike Cintolo for Cabot Growth Investor, and this is what grabbed my attention: “My Expectation: A 25% Jump […]
I’ve been largely trying to hedge against catastrophic declines by using occasional options trades, usually buying put options (as I mentioned I’ve done with Vostok Nafta — to protect against the general downside in Russia I own puts against the RSX index, and have rolled over those puts to another expiration date, those puts, unfortunately, […]
OK, that headline is probably an exaggeration — but it sums up pretty nicely what I thought after listening to Joel Greenblatt speak at the Value Investing Congress this morning, he opened up the conference and did something that will probably garner no headlines: He told us that a diversified portfolio of high quality companies […]
OK, that headline is probably an exaggeration — but it sums up pretty nicely what I thought after listening to Joel Greenblatt speak at the Value Investing Congress this morning, he opened up the conference and did something that will probably garner no headlines: He told us that a diversified portfolio of high quality companies […]
Louis Navellier is never shy about making promises — here’s how his latest ad for his Blue Chip Growth newsletter opens: “Why a tiny office in suburban Israel is our best bet — for repelling the attack — and turning a $7,500 investment into $22,500 by May 2012. “I don’t make this prediction lightly… you […]
This one is probably a few weeks old, going by the share price in the teaser, but it still might be interesting to folks … it is, at the very least, a truly unique investment. Good or bad, you can decide when you know the facts … but certainly unique. The teaser is from Yiannis […]
If I had a nickel for every time some newsletter tout pitched “Silicon Valley’s Next Big Thing” … This ad from the Oxford Club, for their Chairman’s Circle service (a package deal where you pay big $$ up front for lifetime access to all of their newsletters), is all about that next bit thing… and […]
The latest ads from Cabot’s Global Stocks Explorer caught my eye with a “bypass the coronavirus” pitch. Here’s how the ad starts: “Bypass the Coronavirus…with this hidden gem at the heart of ‘the biggest investment boom in history’ “Operating revenue increased over 70%. “Gross profit surged 122%. “Net income was up over 60%. “Total bookings […]
The plan for today? Figure out what other name might be associated with Nikola Tesla, and use it as the name for a new-age company. Venture funding should flow without regard to merit, and you might just be able to go straight to an IPO and buy that private island. Nikola (NKLA) is taken, thanks […]
Timely Schedule of Biotechnology Equitys Gains and LossesThis schedule shall be maintained by any IRR as a(n) event(s) occur(s) in the following format: $XYZ, Link/source,. Calculated columns/cells (TBD) may include: SP, %age SP change, Volume, MC, etc.; brief summary/comment including original comment(s)/thread(s)s/post#(s) . 125-150 characters (max), author. Schedule to exist on stockgumshoe.com/microblog utilizing google drive. This spreadsheet greatly reduce the biotech posts […]
Hi Doc, There is a teaser which talks about 3 hot companies working on pain relieving which can provide huge gains apparently. It mentions about an Arizona and Vancouver-based companies .. http://www.angelnexus.com/o/web/68345/ Google search for delta-9 gave the following companies which are doing phase3 clinical trials .. InMed Pharmaceuticals http://investorshub.advfn.com/InMed-Pharmaceuticals-Inc-IMLFF-28415/ http://www.marketwatch.com/story/inmed-pharma-proprietary-platform-growing-pipeline-low-valuation-2014-10-29 GW Pharma and Insys […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
That’s a subtle headline, right? I already issued a bit of a “brain dump” for the Irregulars this week, on Wednesday instead of Friday, but I couldn’t resist taking a little look at this latest teaser pitch from Patrick Cox for his Transformational Technology Alert. Quite a few readers have been asking about it, and […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] Readers not familiar with Stock Gumshoe usually arrive wondering if the salivation provoked by stock promotional writers for certain companies is justified. […]
I get asked “how do I start investing” questions quite frequently, and also questions about what kinds of online (or other) tools I use to research stocks — so I thought I’d start the discussion about this by sharing a few of my favorite things. First, if you have never invested before and don’t think […]
This thread isnt really a thread at all; although you are welcome to suggest additional rules of engagement. Its aim is to outline what is generally expected of everyone who follows/participates in the main Bio threads, and to inform you where other related specialist threads are lurking. The aim is to avoid the chaos of […]
A friend of mine shares his True Wealth Systems newsletter (Stansberry). Without divulging the entire content (the subject of a previous post from Travis with which I agree), they basically recommend PNC and BAC TARP warrants. I know Travis previously recommended PNC’s. I notice that the newsletter bases its recommendation on a P/B value ranging […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]
Louis Navellier has been around for far longer than most of the newsletter pundits, and his quantitative system has proven itself to be pretty good on average for long periods of time (though it also has taken big hits during rapid market collapses, of course) — we write about his teaser picks from time to […]
I got this in an email, the stock looks strong, what do you think? Please ask Dr. KSS. See the first link. After an exhaustive search I found the ultimate Ebola play and one that will actually make a difference in containing this dreaded disease. When the head of the FDA comes down to your […]
Dear Travis, I represent Valhalla Vaults and would like to share this new investment tool with you and your community : http://www.valhalla-vaults.com/ If you have any questions then please respond and I will answer as soon as possible. Best Regards Adam Bennett – Co Founder Valhalla Vaults About Valhalla Vaults Located in The Hague, NL., […]
Travis- I so much appreciate and enjoy you and the exceptional irregular-shoes here. I have several thoughts/ideas I’d like share: Have you ever considered: 1. A ”Beyond the decimal” (sub penny) and/or pre- and after-market discussion area(s)? 2. An investor tools link area i.e. finvis, barchart, bloomberg, otcmarkets, zacks etc, not only for links but […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though he mentions a couple publicly traded companies). His words and opinions are his own.] Let’s […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. His topics, words and opinions are his own. Enjoy!] It’s the second reel of conspiracy film Shooter, and Mark Wahlberg, whom government schemers are trying to frame for assassination, has just been shot twice. In the back of a stolen FBI car, […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] Tekmira (TKMR) shares have surged in response to announced use of its anti-Ebola RNAi therapeutic. Despite this, share action has occurred in […]
The Value Investing Congress is a two-day conference featuring fairly lengthy, insightful presentations into interesting value investment ideas or bigger picture strategies from some of the most successful hedge fund managers and other value investing “thinkers”. I try to attend every year, and I’m extra delighted that the press and the large corps of bloggers […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Most investors know Muddy Waters and Carson Block, who build his short-selling investment portfolio by pulling away the veil that covered up the many China frauds several years ago, […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Sahm Adrangi is a relatively new guy to the value investing world, Kerrisdale Capital is about five years old and (unlike many) they share their research — particularly on […]
Crocker is a comanager at the Metropolitan Capital hedge fund. His big question is figuring out Groupe Fnac — European retailer and ticketing business (the “Ticketmaster of France). It’s priced as if disaster is around the corner, and it has a huge cash balance. Stores are mainly in France, Spain and Portugal, a few others. […]